DNA diagnostics technique enables healthcare professionals and medical experts to identify various diseases, including cancer, infectious diseases, and myogenic disorders, and to discover the convinient treatment for the same.
DNA diagnostics technique enables healthcare professionals and medical experts to identify various diseases, including cancer, infectious diseases, and myogenic disorders, and to discover the convinient treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics. Polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry are the major technologies of DNA diagnostics. With the emergence of technological development, DNA diagnostic platforms and techniques have improved to a great extent. Doctors and researchers have shifted their focus from traditional diagnostic methods to personalized medicines.
The latest figures suggest that approximately 8.2 million people are living with cancer and 39 million with HIV. These numbers are set to increase consistently; however, advanced automated DNA diagnostics technologies such as next generation sequencing could play a crucial role in diagnosing and curbing these diseases. “Next generation sequencing has had a significant impact on diagnostic procedures and is set to gain momentum in the foreseeable future.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/298
Next generation sequencing not only reduces the cost of sequencing, but increases the throughput as well; it could thus help in bridging the gaps in traditional and personalized medications”, adds the analyst. This makes it a promising investment opportunity for key players. Illumina Inc.'s new cost-effective genome machine HiSeq X Ten -the world’s first DNA crunching supercomputer- is leading to a significant reduction in the price of sequencing a human genome
According to a report published by Allied Market Research, the global DNA diagnostics market size was projected to reach $19 billion with a considerable CAGR from 2014 to 2020. Numerous factors such as increase in applications in clinical diagnosis, rise in technological advancements in DNA sequencing, growth in investments in R&D activities are constantly driving the growth of the global DNA diagnostics market.
Moreover, in 2020, the outbreak of the COVID-19 pandemic led to have a positive impact on the growth of the global DNA diagnostics market, owing to a significant increase in DNA diagnostics technology for the development of various drugs and therapeutics. For instance, in August 2020, Food and Drug Administration (FDA) authorized Helix COVID-19 NGS test under an Emergency Use Authorization (EUA). This is an amplicon based modern sequencing (NGS) test that is able to do qualitative detection of nucleic acid from the coronavirus in upper respiratory specimens from COVID-19 patients. This factor has created enormous opportunity for the growth of the global DNA diagnostics market.
Furthermore, DNA diagnosis offers a promising role in disease management and in the discovery of various disease causing agents, owing to the fact that most of the rare diseases are genetic in origin. the next generation sequencing (NGS) technology has introduced an affordable approach to identify and divide clinically actionable genetic variants across multiple genes at an ultimate speed in a single test. A powerful tool like NGS is a used for decoding a number of diseases. Next generation sequencing increases the throughput, while reducing the cost of sequencing. The optimization of NGS is boosting the growth of the global DNA diagnostics market.
Author’s Bio - Suchita Gupta is an explorer, musician and content writer. While pursuing MBA, she found that nothing satisfies her more than writing on miscellaneous domains. She is a writer by day, and a reader by night. Besides, she can be found entertaining her audience on social media platforms. Find her on LinkedIn & Instagram.